Patents by Inventor Kin Tso

Kin Tso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10941140
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 9, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20210040076
    Abstract: Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Inventors: Lynne Canne Bannen, Minna Bui, Faming Jiang, Kin Tso, Yong Wang, Wei Xu
  • Patent number: 10792282
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 6, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan
  • Publication number: 20200181130
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Application
    Filed: August 26, 2019
    Publication date: June 11, 2020
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • Publication number: 20190359593
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 28, 2019
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20190300518
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 3, 2019
    Applicant: Rigal Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Patent number: 10421752
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: September 24, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • Patent number: 10414753
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 17, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20190256476
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • Patent number: 10370367
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 6, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20190153006
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 23, 2019
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20190060310
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 28, 2019
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan
  • Patent number: 10208074
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Patent number: 10208075
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: February 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20180208613
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20180208612
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 22, 2018
    Publication date: July 26, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Patent number: 10005777
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: June 26, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan, Ryan Kelley
  • Patent number: 9982000
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 29, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Publication number: 20180111917
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 26, 2018
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20180111923
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 26, 2018
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung